Respiratory Diseases Clinical Trial
Official title:
Assessing the Biology of the Injured Lung - Version 1
NCT number | NCT05978011 |
Other study ID # | 2014TP001 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 29, 2014 |
Est. completion date | April 4, 2019 |
Verified date | July 2023 |
Source | Manchester University NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Respiratory diseases are very common and are the third leading cause of death in England. As such, there is strong interest in understanding how respiratory disease occurs. This study intends to understand the changes that occur within diseased/injured lungs obtained from humans. The end goal of this will be to create new drugs to help treat these disorders. Diseased lungs will be obtained from patients receiving a lung transplant. Lungs will either be placed onto a heart-lung machine, or surgically cut in order to create a model of the lung that can be used experimentally in the laboratory. Using a heart-lung machine, lungs can be maintained outside of the human body for a maximum of 12 hours, allowing the direct assessment of the organ. Using this procedure, we aim to understand the processes that occur within a disease, as well as during repair. Using the model of the lung, we will look at how the body's immune system interacts within a diseased lung.
Status | Completed |
Enrollment | 119 |
Est. completion date | April 4, 2019 |
Est. primary completion date | April 4, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients must be able to provide informed consent - Patients must be aged between 18-80 years of age Exclusion Criteria: -Patients under 16 or over 70 years of age |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Manchester University NHS Foundation Trust |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To identify the mechanisms that occur during lung inflammation, injury and repair and the contribution of immune cells to these processes. | Cytokines and chemokines within lungs will be assessed to determine inflammatory profiles. This will be done using luminex arrays that allow quantification of a range of immunologic molecules in bronchoalveolar lavage and perfusate samples. This will provide a broad overview of the prevailing local tissue environment. We will also assess this following immunomodulation as this may be significantly altered by the presence of immunomodulatory therapeutics. | Prior to lung transplantation. | |
Secondary | Characterise the migration and functional profile of immune cells within the inflamed/damaged lung. | Immune cells obtained from the lungs on the EVLP circuit and cells cultured in the air liquid model will be incubated with antibodies that target specific cellular markers for the detection using flow cytometry. Immune cells can then be characterised and their function determined. The behavioural characteristics and activation status of immune cells will also be determined using flow cytometry, ELISpot/ELISA, immunohistochemistry and qPCR. | Prior to lung transplantation | |
Secondary | Assess the effectiveness of therapeutic agents that can repair lung damage. | Diseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). | Prior to lung transplantation | |
Secondary | Trial therapeutic agents that can modulate the effect of immune cells in response to lung tissue injury. | Diseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). | Prior to lung transplantation | |
Secondary | Identify new therapeutic targets/agents that can reduce the incidence/severity of inflammatory respiratory conditions. | PDiseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). | Prior to lung transplantation | |
Secondary | Cut sections of the lung to culture in an in vitro lung model to assess the effect of various different mechanisms of injury on the function and characteristics of immune cells. | Lungs will be dissected to be used in an in vitro model, generating a morphologically accurate model of the lung. This model will then be used to assess immune cell characteristics. | Prior to lung transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04461821 -
Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
|
||
Recruiting |
NCT06267859 -
Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children
|
Early Phase 1 | |
Completed |
NCT04386408 -
Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections
|
Phase 1 | |
Recruiting |
NCT06229613 -
Exhaled Breath Aerosol for the Etiological Diagnosis of Respiratory Tract Infections: a Pilot Study
|
||
Completed |
NCT02084043 -
In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation
|
N/A | |
Completed |
NCT01113255 -
Validation of a Simulated Clinical Evaluation of Ventilators
|
Phase 2/Phase 3 | |
Completed |
NCT00988000 -
Initial Specialist Telephone Consultation With New Patients in Secondary Care
|
N/A | |
Completed |
NCT06454513 -
Efficacy of Different Anesthesia Methods in Transbronchial Biopsy
|
||
Completed |
NCT02723890 -
The Efficacy and Safety of Using the Novel Tyto Device
|
N/A | |
Completed |
NCT00719784 -
Vibration Response Imaging in the Diagnosis of Pulmonary Disease
|
N/A | |
Completed |
NCT00823056 -
The Effect of Probiotics on Infections in Toddlers
|
Phase 3 | |
Recruiting |
NCT06366113 -
Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Recruiting |
NCT05175313 -
Transthoracic Ultrasonography Findings and Their Relation to Spirometric Indices in Patients With Obstructive and Restrictive Respiratory Diseases
|
||
Completed |
NCT02754947 -
Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
|
||
Completed |
NCT01255592 -
Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
|
Phase 2 | |
Completed |
NCT00840723 -
Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects
|
N/A | |
Recruiting |
NCT02717650 -
The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis.
|
N/A | |
Completed |
NCT01196533 -
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
|
N/A | |
Completed |
NCT02406053 -
Oxidative Damage and Antioxidant Mechanisms in COPD
|
N/A | |
Completed |
NCT01734629 -
Pulmonary Disease in Patients Referred for Coronary CT
|
N/A |